The stock of Moderna Inc (NASDAQ: MRNA) has decreased by -12.37 when compared to last closing price of 31.12.Despite this, the company has seen a loss of -20.19% in its stock price over the last five trading days. cnbc.com reported 2025-03-31 that Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
Is It Worth Investing in Moderna Inc (NASDAQ: MRNA) Right Now?
The 36-month beta value for MRNA is at 2.18. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 17 as “hold,” and 1 as “sell.”
The public float for MRNA is 341.66M, and currently, shorts hold a 13.72% of that float. The average trading volume for MRNA on March 31, 2025 was 11.34M shares.
MRNA’s Market Performance
MRNA’s stock has seen a -20.19% decrease for the week, with a -11.92% drop in the past month and a -32.55% fall in the past quarter. The volatility ratio for the week is 5.65%, and the volatility levels for the past 30 days are at 6.34% for Moderna Inc The simple moving average for the past 20 days is -18.12% for MRNA’s stock, with a -56.96% simple moving average for the past 200 days.
Analysts’ Opinion of MRNA
Many brokerage firms have already submitted their reports for MRNA stocks, with Citigroup repeating the rating for MRNA by listing it as a “Neutral.” The predicted price for MRNA in the upcoming period, according to Citigroup is $40 based on the research report published on March 13, 2025 of the current year 2025.
Barclays, on the other hand, stated in their research note that they expect to see MRNA reach a price target of $45, previously predicting the price at $111. The rating they have provided for MRNA stocks is “Equal Weight” according to the report published on February 18th, 2025.
Goldman gave a rating of “Neutral” to MRNA, setting the target price at $51 in the report published on January 29th of the current year.
MRNA Trading at -21.20% from the 50-Day Moving Average
After a stumble in the market that brought MRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.00% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares sank -9.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.11% lower at present.
During the last 5 trading sessions, MRNA fell by -20.08%, which changed the moving average for the period of 200-days by -81.60% in comparison to the 20-day moving average, which settled at $33.31. In addition, Moderna Inc saw -34.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNA starting from Bancel Stephane, who purchase 160,314 shares at the price of $31.22 back on Mar 03 ’25. After this action, Bancel Stephane now owns 9,210,686 shares of Moderna Inc, valued at $5,004,318 using the latest closing price.
SAGAN PAUL, the Director of Moderna Inc, purchase 31,620 shares at $31.76 during a trade that took place back on Mar 03 ’25, which means that SAGAN PAUL is holding 312,027 shares at $1,004,251 based on the most recent closing price.
Stock Fundamentals for MRNA
Current profitability levels for the company are sitting at:
- -1.22 for the present operating margin
- 0.52 for the gross margin
The net margin for Moderna Inc stands at -1.1. The total capital return value is set at -0.33. Equity return is now at value -28.77, with -21.87 for asset returns.
Based on Moderna Inc (MRNA), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -4.23. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -164.38.
Currently, EBITDA for the company is -3.39 billion with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 2.95. The receivables turnover for the company is 9.02for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.67.
Conclusion
In conclusion, Moderna Inc (MRNA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
